

Recommendations from York and Scarborough Medicines Commissioning Committee December 2019

	Drug name	Indication	Recommendation, rationale and place in therapy	RAG status	Potential full year cost impact
CCG commissioned Technology Appraisals					
1.	TA610: Pentosan polysulfate sodium for treating bladder pain syndrome		<p>Pentosan polysulfate sodium is recommended as an option for treating bladder pain syndrome with glomerulations or Hunner's lesions in adults with urinary urgency and frequency, and moderate to severe pain, only if:</p> <p>their condition has not responded to an adequate trial of standard oral treatments</p> <ul style="list-style-type: none"> it is not offered in combination with bladder instillations any previous treatment with bladder instillations was not stopped because of lack of response it is used in secondary care and the company provides pentosan polysulfate sodium according to the commercial arrangement. 	RED	<p>Cost impact expected to be less than £9,000 per 100,000 population according to NICE</p> <p>The technology is a further treatment option after standard oral treatments have been unsuccessful. The overall cost of treatment is not deemed to be significant because there is a reduction in the number of patients requiring bladder instillations.</p>
2.	TA613: Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema in phakic eyes after an inadequate response to previous therapy		<p>Fluocinolone acetonide intravitreal implant is not recommended as an option for treating chronic diabetic macular oedema that is insufficiently responsive to available therapies in an eye with a natural lens (phakic eye).</p>	BLACK for this indication	No cost impact to CCGs expected as not recommended by NICE for this indication.
NHSE commissioned Technology Appraisals – for noting					
3.	TA611: Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer		<p>Rucaparib is recommended for use within the Cancer Drugs Fund as an option for maintenance treatment of relapsed platinum-sensitive high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer that has responded to platinum-based chemotherapy in adults, only if the conditions in the managed access agreement for rucaparib are followed.</p>	RED	No cost impact to CCGs as NHS England commissioned.
4.	TA612: Neratinib for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant		<p>Neratinib is recommended as an option for the extended adjuvant treatment of hormone receptor-positive HER2-positive early stage breast cancer in adults who completed adjuvant trastuzumab-based therapy less than 1 year ago only if:</p>	RED	No cost impact to CCGs as NHS England commissioned.

	trastuzumab	<ul style="list-style-type: none"> trastuzumab is the only HER2-directed adjuvant treatment they have had, and if they had neoadjuvant chemotherapy-based regimens, they still had residual invasive disease in the breast or axilla following the neoadjuvant treatment, and the company provides neratinib according to the commercial arrangement. 		
Formulary applications or amendments/pathways/guidelines				
5.	Oral Rifampicin – change in RAG status	Approved change from RED to AMBER Shared Care for use on recommendation of microbiologists. This is to improve ease of access for patients who require longer courses of treatment. Requires shared care due to monitoring requirements with long courses e.g. LFTs. IV to remain RED and to remain RED when used for TB.	AMBER SHARED CARE	Cost for 7 days of oral rifampicin = £17.34 to £34.69 Expect <10 patients per year.
6.	Insulin Toujeo Double Star	Approved. Note 1.5ml already on the formulary as a GREEN drug.	GREEN	No cost impact to CCGs as same price as 1.5ml pen already on the formulary.
7.	Nadolol	Approved Nadolol for Patients with Long QT syndrome as per Tertiary Centre position in Leeds	AMBER Specialist Initiation	Approx 5 patients year = £720 across VoY and ScR CCGs.
8.	Biologics Pathway for Crohn's disease and Ulcerative colitis	Approved. Reflects NICE TA guidance and most cost-effective agents used first.	n/a	No significant cost to CCGs expected.
9.	Lumacaftor/Ivacaftor; and Tezacaftor/Ivacaftor	Approved updating formulary to mirror NHSE Clinical Commissioning Urgent Policy Statement: Cystic Fibrosis Modulator Therapies NHS England URN: 190137P	RED	No cost impact to CCGs as NHS England commissioned.
10.	Testosterone Esters (Sustanon) for the treatment of delayed puberty	To mirror Leeds APC formulary decision from Oct 2019	AMBER Specialist Initiation	No significant cost impact to CCGs expected. Sustanon® 250, 250mg/mL solution for injection given monthly = £2.45
11.	Methotrexate (oral) for the treatment of non-oncology indications in paediatrics	To mirror Leeds APC formulary decision from Oct 2019	AMBER SHARED CARE	No significant cost impact to CCGs expected. 2.5mg tablets x 28 = £2.12
13.	Dolutegravir/ lamivudine 50mg/300mg F/C tablet (Dovato) for HIV-1 infection in	To mirror Leeds APC formulary decision from Oct 2019	RED	No cost impact to CCGs as NHS England commissioned.

	patients with no known or suspected resistance to integrase inhibitors or lamivudine.			
14.	Nicotinamide topical gel e.g. Freederm for mild to moderate acne (in line with NHSE Items available to purchase over the counter)	To mirror Leeds APC formulary decision from Oct 2019	BLACK	No cost impact expected.
15.	Aliskerin	To add as BLACK as use not recommended in NHSE guidance and to mirror Leeds APC formulary decision from Oct 2019.	BLACK	No cost impact expected.
16.	Methadone Injection	Agreed to change from RED to AMBER SR for use in substance misuse palliative care patients who cannot take oral methadone.	AMBER Specialist Recommendation	No cost impact expected. Not to exceed 2 patients per year.